Table 2.

 Discounted costs and quality adjusted life years (QALYs) gained by human papillomavirus vaccination in base case programme (vaccination of girls aged 12 years with no catch-up programme, 80% effective vaccine coverage, quadrivalent vaccine, 100 year time horizon, and 3.5% discount rate for costs and benefits) assuming vaccine protection lasts an average of 20 years

Parameter	Mean	Median	5% centile	95% centile
Cost of vaccine (£m)	2225	2225	1937	2513
Cost saved (£m):
Reduced lesion screening and treatment	−48	−47	−176	61
Cancers prevented	−135	−118	−274	−55
Warts prevented	−229	−232	−300	−151
Net cost (£m)	1813	1816	1455	2169
Cost saved (£m):
Unscreened vaccinees	−16	−14	−34	−7
Non-cervical cancers prevented	−42	−34	−96	−16
Non-vaccine type infections prevented	−61	−55	−110	−34
Net cost with unscreened, non-cervical cancers, and non-vaccine type infections (£m)	1694	1701	1288	2074
QALYs gained:
Reduced lesion screening and treatment	10 987	9 617	−783	27 607
Cancers prevented	63 353	60 976	44 326	90 051
Warts prevented	9530	9233	4434	15 711
Total QALYs gained	83 871	80 690	58 856	119 167
QALYS gained:
Unscreened cohort	7444	6778	5048	12 137
Non-cervical cancers prevented	18 033	15 171	11 085	34 924
Non-vaccine type infections prevented (£m)	8799	7989	5378	15 531
Total QALYs gained with unscreened, non-cervical cancers, and non-vaccine type infections	118 146	111 304	82 874	177 199

£1.00 (€1.26; $1.98). Mean, median, 5% and 95% centiles of 50 000 meta-scenarios representing uncertainty in epidemiological and economic parameters are reported.